The door into the second encounter of Sundered Doctrine is a small test, set to teach you the mechanics you need to know. You ...
London with the kids this half-term - From mesmerising museums to animal encounters, we’ve selected some of the best things ...
Obesity drug developer Metsera and kidney disease biotech Maze Therapeutics priced their Nasdaq IPOs on Thursday evening.
Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...
Experience movie monsters from the studio that invented the horror genre. Experience some of the scariest monsters in the world in this immensely themed year-round maze. Based off Universal’s long and ...
Daiichi Sankyo’s board of directors followed the nomination committee’s report in making the appointment. Credit: ArDanMe/Shutterstock. Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed ...
Vertex has set the therapy’s wholesale acquisition cost at $15.50 per 50mg pill. Credit: © 2025 Vertex Pharmaceuticals Incorporated. All Rights Reserved. The US ...
Even tenants who make a point of standing up for their rights can still find themselves at the mercy of power dynamics in Toronto’s precarious housing system. Amelia, a 26-year-old who moved here last ...
Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial public offering, set to be the first U.S.-based biotech firm to debut this ...
Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial. The Bay Area-based biotech unveiled its ambition earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback